<DOC>
	<DOCNO>NCT02654639</DOCNO>
	<brief_summary>Phase II study TAS-102 plus bevacizumab switch maintenance therapy patient mCRC</brief_summary>
	<brief_title>Ph 2 Study TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Study Drug : TAS-102 ( trifluridine tipiracil hydrocholoride ) bevacizumab Dosing Details : Starting dose TAS-102 35 mg/m2 administer orally twice daily , meal , 5 day week 2 day rest 14 day , follow 14 day rest ( 1 treatment cycle ) . Bevacizumab 5 mg/kg intravenously every 14 day . The treatment cycle repeat every 28 day . Patients may take TAS-102 plus bevacizumab exhibit progression disease , withdraw consent , experience unacceptable toxicity.This single arm study . All patient receive study treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Inclusion criterion : Written inform consent Histologically proven , unresectable , evaluable metastatic colorectal cancer 16 20 week firstline therapy oxaliplatin , and/or irinotecanbased flourorpyrimidinecontaining chemotherapy plus Bevacizumab Patients must stable disease ( well ) initial induction chemotherapy firstline chemotherapy . No progressive disease time initiation maintenance therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate organ marrow function Women childbearing potential men must agree avoid pregnancy Patient must start maintenance therapy least 14 day last administered induction chemotherapy later 30 day . Exclusion Criteria Patients whose tumor progress firstline treatment Patients active concurrent malignancy , superficial , noninvasive squamous cell carcinoma skin uterine cervix , within past three year . Women pregnant lactate Unstable heart disease Uncontrolled active infection require antibiotic within one week prior first dose . Patients active CNS malignancy . Persistent protein urine Patients bowel obstruction uncontrolled vomit . Patients serious psychiatric medical condition could interfere treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Advanced Colorectal Cancer</keyword>
</DOC>